Aug 24, 2020 7:57pm EDT Nexera Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants
Aug 24, 2020 8:00am EDT Nexera Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medications (Basic Plan and Institutions)
Aug 11, 2020 5:19pm EDT Nexera Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of Fiscal 2021
Aug 11, 2020 8:30am EDT Nexera Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th
Jul 09, 2020 8:30am EDT Nexera Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Public Drug Plan Formularies
Jun 22, 2020 5:15pm EDT Nexera Pharmaceuticals Reports Record Revenue of $25.6 Million and $4.2 Million of Adjusted EBITDA* for the Fourth Quarter of Fiscal 2020
